001     141707
005     20240229105129.0
024 7 _ |a 10.1001/jamaoncol.2018.1771
|2 doi
024 7 _ |a pmid:29931120
|2 pmid
024 7 _ |a 2374-2437
|2 ISSN
024 7 _ |a 2374-2445
|2 ISSN
024 7 _ |a altmetric:43962879
|2 altmetric
037 _ _ |a DKFZ-2018-01978
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Group, Premenopausal Breast Cancer Collaborative
|b 0
|e Collaboration Author
245 _ _ |a Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women.
260 _ _ |a Chicago, Ill.
|c 2018
|b American Medical Association
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1542961267_22900
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover effect exists, with risk reduction before and risk increase after menopause. The inverse association with premenopausal breast cancer risk is poorly characterized but might be important in the understanding of breast cancer causation.To investigate the association of BMI with premenopausal breast cancer risk, in particular by age at BMI, attained age, risk factors for breast cancer, and tumor characteristics.This multicenter analysis used pooled individual-level data from 758 592 premenopausal women from 19 prospective cohorts to estimate hazard ratios (HRs) of premenopausal breast cancer in association with BMI from ages 18 through 54 years using Cox proportional hazards regression analysis. Median follow-up was 9.3 years (interquartile range, 4.9-13.5 years) per participant, with 13 082 incident cases of breast cancer. Participants were recruited from January 1, 1963, through December 31, 2013, and data were analyzed from September 1, 2013, through December 31, 2017.Body mass index at ages 18 to 24, 25 to 34, 35 to 44, and 45 to 54 years.Invasive or in situ premenopausal breast cancer.Among the 758 592 premenopausal women (median age, 40.6 years; interquartile range, 35.2-45.5 years) included in the analysis, inverse linear associations of BMI with breast cancer risk were found that were stronger for BMI at ages 18 to 24 years (HR per 5 kg/m2 [5.0-U] difference, 0.77; 95% CI, 0.73-0.80) than for BMI at ages 45 to 54 years (HR per 5.0-U difference, 0.88; 95% CI, 0.86-0.91). The inverse associations were observed even among nonoverweight women. There was a 4.2-fold risk gradient between the highest and lowest BMI categories (BMI≥35.0 vs <17.0) at ages 18 to 24 years (HR, 0.24; 95% CI, 0.14-0.40). Hazard ratios did not appreciably vary by attained age or between strata of other breast cancer risk factors. Associations were stronger for estrogen receptor-positive and/or progesterone receptor-positive than for hormone receptor-negative breast cancer for BMI at every age group (eg, for BMI at age 18 to 24 years: HR per 5.0-U difference for estrogen receptor-positive and progesterone receptor-positive tumors, 0.76 [95% CI, 0.70-0.81] vs hormone receptor-negative tumors, 0.85 [95% CI: 0.76-0.95]); BMI at ages 25 to 54 years was not consistently associated with triple-negative or hormone receptor-negative breast cancer overall.The results of this study suggest that increased adiposity is associated with a reduced risk of premenopausal breast cancer at a greater magnitude than previously shown and across the entire distribution of BMI. The strongest associations of risk were observed for BMI in early adulthood. Understanding the biological mechanisms underlying these associations could have important preventive potential.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Schoemaker, Minouk J
|b 1
700 1 _ |a Nichols, Hazel B
|b 2
700 1 _ |a Wright, Lauren B
|b 3
700 1 _ |a Brook, Mark N
|b 4
700 1 _ |a Jones, Michael E
|b 5
700 1 _ |a O'Brien, Katie M
|b 6
700 1 _ |a Adami, Hans-Olov
|b 7
700 1 _ |a Baglietto, Laura
|b 8
700 1 _ |a Bernstein, Leslie
|b 9
700 1 _ |a Bertrand, Kimberly A
|b 10
700 1 _ |a Boutron-Ruault, Marie-Christine
|b 11
700 1 _ |a Braaten, Tonje
|b 12
700 1 _ |a Chen, Yu
|b 13
700 1 _ |a Connor, Avonne E
|b 14
700 1 _ |a Dorronsoro, Miren
|b 15
700 1 _ |a Dossus, Laure
|b 16
700 1 _ |a Eliassen, A Heather
|b 17
700 1 _ |a Giles, Graham G
|b 18
700 1 _ |a Hankinson, Susan E
|b 19
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 20
|u dkfz
700 1 _ |a Key, Timothy J
|b 21
700 1 _ |a Kirsh, Victoria A
|b 22
700 1 _ |a Kitahara, Cari M
|b 23
700 1 _ |a Koh, Woon-Puay
|b 24
700 1 _ |a Larsson, Susanna C
|b 25
700 1 _ |a Linet, Martha S
|b 26
700 1 _ |a Ma, Huiyan
|b 27
700 1 _ |a Masala, Giovanna
|b 28
700 1 _ |a Merritt, Melissa A
|b 29
700 1 _ |a Milne, Roger L
|b 30
700 1 _ |a Overvad, Kim
|b 31
700 1 _ |a Ozasa, Kotaro
|b 32
700 1 _ |a Palmer, Julie R
|b 33
700 1 _ |a Peeters, Petra H
|b 34
700 1 _ |a Riboli, Elio
|b 35
700 1 _ |a Rohan, Thomas E
|b 36
700 1 _ |a Sadakane, Atsuko
|b 37
700 1 _ |a Sund, Malin
|b 38
700 1 _ |a Tamimi, Rulla M
|b 39
700 1 _ |a Trichopoulou, Antonia
|b 40
700 1 _ |a Ursin, Giske
|b 41
700 1 _ |a Vatten, Lars
|b 42
700 1 _ |a Visvanathan, Kala
|b 43
700 1 _ |a Weiderpass, Elisabete
|b 44
700 1 _ |a Willett, Walter C
|b 45
700 1 _ |a Wolk, Alicja
|b 46
700 1 _ |a Yuan, Jian-Min
|b 47
700 1 _ |a Zeleniuch-Jacquotte, Anne
|b 48
700 1 _ |a Sandler, Dale P
|b 49
700 1 _ |a Swerdlow, Anthony J
|b 50
773 _ _ |a 10.1001/jamaoncol.2018.1771
|g Vol. 4, no. 11, p. e181771 -
|0 PERI:(DE-600)2810928-4
|n 11
|p e181771
|t JAMA oncology
|v 4
|y 2018
|x 2374-2437
909 C O |o oai:inrepo02.dkfz.de:141707
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b JAMA ONCOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 20
|0 StatID:(DE-HGF)9920
|2 StatID
|b JAMA ONCOL : 2017
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21